Robert F. Apple - Mar 3, 2022 Form 4 Insider Report for ANTARES PHARMA, INC. (ATRS)

Role: President & CEO, Director
Signature: /s/ Lisa M. Kallebo as attorney-in-fact for Robert F. Apple
Stock symbol: ATRS
Transactions as of: Mar 3, 2022
Transactions value $: -$143,241
Form type: 4
Date filed: 3/4/2022, 05:38 PM
Previous filing: Feb 18, 2022
Next filing: May 26, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATRS	Common Stock	Award	$0	+86.8K	+3.56%	$0.00	2.53M	Mar 3, 2022	Direct	F1
transaction	ATRS	Common Stock	Tax liability	-$143K	-37.7K	-1.49%	$3.80	2.49M	Mar 3, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 3, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold.

Content

On June 13, 2019, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2021. The number of shares acquired represent the total number of shares earned upon achievement of one of the performance goals, which was certified and vested on March 3, 2022. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liabilities in connection with the vesting of the performance stock unit award and were not actually sold.